Patent ID: 7030133
Filing Date: 2006-04-18
Classification: A23L,A61K,A61P

Abstract:
1. A method of inhibiting formation of glycation endproducts or protein crosslinking in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of: LR103: 1-[(4-chlorobenzyl)-3-(3,4-dichlorophenylureido)]-4-phenoxyisobutyric acid, LR104: 4-(4-fluoro-3-chlorophenylurido)phenoxyisobutyrylamidophenyl-2-carboxylic acid, LR105: 1[(2-fluoro-6-chlorobenzyl)-3-(3,4-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR106: 4-(4-chlorobenzylaminophenoxyisobutyric) acid, LR107: 2-chlorobenzene-1,4-bis(4-ureidophenoxyisobutyric acid), LR108: 1-[(4-chlorobenzyl)-3-(3,5-dichlorophenyureido)]-4-phenoxyisobutyric acid, LR109: 1-[(2-fluoro-6-chlorobenzyl)-3-(2-fluoro-6-chlorophenylureido)]-4-phenoxyisobutyric acid, LR110: 4-(1,2,3,4-tetrahydroacridine-9-carboxamidophenoxyisobutyric) acid, LR111: 8-quinolinoxy acetic acid, LR112: 4,4′-bis[(methyleneoxyethyleneamino)phenoxyl]isobutyric acid, LR113: L-8-quinolinolyl(acetylhistidine), LR114: 4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]-2-hydroxybenzene-4-carboxylic acid, and LR115: L, α-4-[(3,5-dichlorophenyureido)phenoxyisobutyrylamido]phenylalanine.